Pancreatic Cancer Research

ResearcherParacelsus Medical UniversityNo recent work listed

Daniel Neureiter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9155-5762; OpenAlex author ID A5010743128. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
9
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers

Papers 5

  1. Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.09.004↗
  2. Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Co-author DOI 10.1177/15330338211042139↗
  3. Pancreatic cancer in young adults: changes, challenges, and solutions. Last author DOI 10.2147/ott.s176700↗
  4. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. Co-author DOI 10.3748/wjg.v20.i24.7830↗
  5. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Last author DOI 10.3892/ijo.2012.1648↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Konstantin Schlick · 3 shared papers, 2019–2021 · strength 0.37
  2. Lukas Weiß · 2 shared papers, 2021 · strength 0.27
  3. Richard Greil · 2 shared papers, 2021 · strength 0.27
  4. Alexander Egle · 1 shared paper, 2021 · strength 0.11
  5. Stefan Stättner · 1 shared paper, 2019 · strength 0.10
  6. Florian Primavesi · 1 shared paper, 2019 · strength 0.10
  7. Karl Quint · 1 shared paper, 2012 · strength 0.03
  8. Pietro Di Fazio · 1 shared paper, 2012 · strength 0.03
  9. Felix Rückert · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.